{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["He Q"],"funding":["National Natural Science Foundation of China"],"pagination":["24"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10773052"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(1)"],"pubmed_abstract":["<h4>Background</h4>There are accumulating type 2 diabetes patients who have osteoporosis simultaneously. More effective therapeutic strategies should be discovered. Biochanin A (BCA) has been indicated that can play a role in improving metabolic disorders of type 2 diabetes and preventing osteoporosis. But whether BCA can treat type 2 diabetic osteoporosis has not been studied.<h4>Purpose</h4>To investigate if the BCA can protect against type 2 diabetic osteoporosis and clarify the mechanism.<h4>Methods</h4>Micro-CT and histology assays were performed to detect the trabecular bone and analyze the bone histomorphology effect of BCA. CCK-8 assay was performed to detect the toxicity of BCA. TRAcP staining, immunofluorescence and hydroxyapatite resorption assay were used to observe osteoclasts"],"journal":["BMC complementary medicine and therapies"],"pubmed_title":["Biochanin A abrogates osteoclastogenesis in type 2 diabetic osteoporosis via regulating ROS/MAPK signaling pathway based on integrating molecular docking and experimental validation."],"pmcid":["PMC10773052"],"funding_grant_id":["NO. 82074462","82374470"],"pubmed_authors":["Yang J","Pan Z","Chen P","Zhang N","Lin Y","Wang H","He Q","Chen C","Chen B","Li M","Li S","Xiao J","Chen W","Zeng J"],"additional_accession":[]},"is_claimable":false,"name":"Biochanin A abrogates osteoclastogenesis in type 2 diabetic osteoporosis via regulating ROS/MAPK signaling pathway based on integrating molecular docking and experimental validation.","description":"<h4>Background</h4>There are accumulating type 2 diabetes patients who have osteoporosis simultaneously. More effective therapeutic strategies should be discovered. Biochanin A (BCA) has been indicated that can play a role in improving metabolic disorders of type 2 diabetes and preventing osteoporosis. But whether BCA can treat type 2 diabetic osteoporosis has not been studied.<h4>Purpose</h4>To investigate if the BCA can protect against type 2 diabetic osteoporosis and clarify the mechanism.<h4>Methods</h4>Micro-CT and histology assays were performed to detect the trabecular bone and analyze the bone histomorphology effect of BCA. CCK-8 assay was performed to detect the toxicity of BCA. TRAcP staining, immunofluorescence and hydroxyapatite resorption assay were used to observe osteoclasts","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jan","modification":"2026-06-02T06:59:56.303Z","creation":"2025-04-04T19:22:30.751Z"},"accession":"S-EPMC10773052","cross_references":{"pubmed":["38191438"],"doi":["10.1186/s12906-023-04332-x"]}}